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Vascular disrupting agents (VDAs) are able to affect selectively tumour endothelial cell morphology resulting in vessel occlusion and
widespread tumour cell necrosis. However, single-agent antitumour activity of VDAs is typically limited, as tumour regrowth occurs
rapidly following drug treatment. To improve the therapeutic effectiveness of VDAs, we investigated liposomal targeting using
ZD6126 as a model VDA. ZD6126 is a phosphate-prodrug of the tubulin-binding vascular disrupting agent ZD6126 phenol. ZD6126
was encapsulated into long circulating PEG-liposomes for passive targeting and PEG-liposomes conjugated with peptide ligands
containing the RGD-motif for active targeting to av-integrins on tumour endothelial cells. ZD6126 could be stably encapsulated, and
liposomes displayed minimal leakage in vitro (o10% in 3 weeks). In vivo, upon intravenous injection, free ZD6126 was rapidly
converted into ZD6126 phenol, which was cleared from the circulation within minutes. In contrast, ZD6126 encapsulated into either
RGD-targeted or PEG liposomes showed prolonged blood circulation times (t1/2¼10h), and ZD6126 phenol exposure was also
prolonged (t1/2¼8h). Both liposomal formulations displayed tumour accumulation plus hepatosplenic uptake by local macrophages.
The altered pharmacokinetics and tissue distribution profiles of both liposomal ZD6126 formulations resulted both in single-dose and
multiple-dose regimes, in improved therapeutic efficacy in established murine B16.F10 melanomas compared with free ZD6126. The
passively and actively targeted liposomes showed equal antitumour efficacy, indicating that delivery of ZD6126 to the tumour tissue
may suffice to disrupt tumour blood vessels without the need for specific targeting to the tumour endothelium.
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Blood vessel development is important for tumour progression.
Therapies that specifically focus on targeting tumour vasculature
have been extensively explored since the early 1970s (Folkman,
1971). Vascular-targeted therapies can be divided into two distinct
groups: anti-angiogenic agents and vascular disrupting agents.
Anti-angiogenic agents prevent new blood vessel growth by
interfering with angiogenic stimuli and appear most beneficial in
early-stage disease. To prevent tumour growth, these agents need
to be dosed chronically over prolonged periods of time to
continuously obstruct formation of new tumour blood vessels
(Drixler et al, 2000). Vascular disrupting agents, on the other hand,
have an immediate destructive effect. They disrupt established
tumour blood vessels, inducing vascular collapse leading to
tumour cell death (Siemann et al, 2005; Tozer et al, 2005).
Tumour vessels are different from quiescent endothelium at
various levels. For example, tumour vasculature generally lacks the
structural support of mature vessels, is more permeable, and
also expresses distinct antigens (Carmeliet and Jain, 2000).
Furthermore, immature angiogenic endothelial cells rely on a
microtubule cytoskeleton to support their elongated shape.
Microtubule-destabilising vascular disrupting agents (VDAs) act
through inhibition of tubulin polymerisation, which results in the
activation of RhoA, an intracellular coordinator of cytoskeletal
rearrangements, and its downstream effectors (Lippert, 2006).
Rearrangement of the cytoskeleton initiates loss of the elongated
endothelial cell shape (‘rounding up’) and subsequent basement
membrane exposure. Exposed basement membranes may induce
thrombus formation causing blood vessel congestion, blood flow
reduction, and hypoxia resulting in necrosis and tumour cell
death. Certain tubulin binding microtubule-destabilizing agents
(including colchicine and vincristine) have only shown VDA
effects at doses near the maximum tolerated dose (MTD) (Thorpe
et al, 2003). In contrast, second-generation tubulin binding
microtubule-destabilizing agents display vascular disrupting
activity in tumours at doses well below their MTD.
A number of second-generation compounds have been
extensively studied in preclinical settings including ZD6126,
Combretastatin A4 phosphate, AVE8062, ABT-751, and OXi4503.
Pronounced antitumour effects were seen in a wide variety of
preclinical tumour models (Blakey et al, 2002b; Hill et al, 2002a,b).
Despite up to 95% necrosis in the tumour mass, tumour
progression still occurred within a few days of treatment.
To improve their effectiveness, VDAs have been extensively
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sstudied in combination with other therapies including radiation
(Siemann and Rojiani, 2002b; Wachsberger et al, 2005), chemo-
therapeutic agents (Blakey et al, 2002b; Siemann and Rojiani,
2002a; Taraboletti et al, 2005), and anti-angiogenic drugs (Siemann
and Shi, 2004). Sengupta et al (2005) showed improved therapeutic
index and reduced toxicity in a co-encapsulated nanoscale
formulation of combretastatin A4 and doxorubicin. Because peak
blood flow reduction is obtained within a few hours of treatment
with a VDA (Goertz et al, 2002), and total repopulation of the
tumour generally is accomplished within 72h after treatment
(McIntyre et al, 2004), there is a limited time frame for
combination therapy strategies to be successful, at least in
preclinical models.
In clinical trials, this class of compounds has shown marked
reductions in tumour blood flow, although single-agent antitu-
mour efficacy has been very limited, as predicted from the
preclinical models (Gould et al, 2007). We considered that
changing the tissue distribution of VDAs by targeting the drug
to the tumour vasculature could be a strategy to improve the
therapeutic effectiveness of these compounds. One of the most
attractive drug delivery systems for tumour targeting are
liposomes, as they show a relative high accumulation and have a
unparalleled circulatory half life (Allen and Cullis, 2004).
Liposomes are spherical nanoparticles containing a phospholipid
bilayer surrounding an aqueous core. Addition of a poly(ethylene
glycol) (PEG)-coating delays uptake by the mononuclear phago-
cyte system (MPS), resulting in prolonged circulation time and
enhanced tumour accumulation due to the enhanced permeability
and retention effect (Vail et al, 2004; Minchinton and Tannock,
2006). Furthermore, liposomes can be specifically targeted by
coupling peptide ligands or antibodies to the outer surface.
Previously, the chemotherapeutic agent doxorubicin was encapsu-
lated into long-circulating liposomes. Liposomal delivery of
cytotoxic agent doxorubicin resulted in higher tumour drug levels
and enhanced therapeutic efficacy. This is the result of the altered
pharmacokinetics and tissue distribution profile of the liposomal
formulation (Park, 2002; Safra, 2003; Ewer et al, 2004). Doxo-
rubicin-containing liposomes are clinically used for the treatment
of several types of cancer (Northfelt et al, 1998; Perez et al, 2002;
Thigpen et al, 2005).
In this study, we investigated whether the therapeutic effective-
ness of ZD6126 could be increased by targeting the agent to the
tumour tissue. ZD6126 is a water-soluble phosphate prodrug of the
tubulin-binding agent ZD6126-phenol (N-acetylcolchinol), which
is formed after rapid hydrolysis of the prodrug by phosphatases
present in circulating blood.
Intravenously (i.v.) injected ZD6126 has a very fast elimination
rate from the blood in both rats and humans with t1/2 values of less
than 1h. Altering pharmacokinetics and the tissue distribution
profile of ZD6126 by encapsulation into long circulating
PEG-liposomes could improve therapeutic efficacy. To further
improve site-specific delivery to tumour angiogenic endothelium,
we have additionally coupled cyclic RGD (Arg-Gly-Asp) peptides
to the surface of the PEG liposomes, which specifically bind to
av-integrins that are overexpressed on the surface of angiogenic
endothelial cells (Thorpe et al, 2003).
MATERIALS AND METHODS
Preparation of ZD6126-encapsulated liposomes
Long circulating liposomes were prepared as described previously
(Schiffelers et al, 2005). Composition of the liposomes was
dipalmitoylphosphatidylcholine (Lipoid GmbH, Ludwigshafen,
Germany), cholesterol (Sigma, St Louis, MO, USA), PEG 2000-
distearoylphosphatidylethanolamine (Lipoid GmbH), and in case
of ligand targeted liposomes maleimide-PEG 2000, distearoyl-
phosphatidylethanolamine (Lipoid GmbH) was additionally added.
Total molar ratio was 1.85:1:0.15 and 1.85:1:0.075:0.075,
respectively, and total lipid amount 100mMml
 1. After dissolving
the lipids in chloroform:methanol (2:1 vol:vol), a lipid film
was made under reduced pressure on a rotary evaporator and
dried under a stream of nitrogen. Liposomes were formed
by addition of an aqueous solution (40–80mgml
 1)o f
ZD6126. Approximately 150-nm-sized liposomes (Polydispersity
index o0.2) were obtained by repeated extrusion. Encapsulated
ZD6126 concentration was determined by high-pressure liquid
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Figure 1 In vitro cell toxicity (XTT) after 24h incubation with free
ZD6126 (’) PEG-liposomal (J) and RGD-PEG-liposomal (,) ZD6126
formulations. These were tested at a range of concentrations and for
following cell lines: human umbilical vein endothelial cells (HUVECs) (A)
murine melanoma cell line B16.F10 (B), and murine tumour-derived
macrophages J774A.1 (C). Data are calculated against buffer-treated
control cells (set to 100% viability).
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schromatography (Xterra RP18 3.5mm, 150mm long 4.6mm ID
column) using a gradient of 80% 1000:1 water:trifluoroacetic
acid (solvent A)/20% 1000:1 acetonitrile:trifluoroacetic acid
(solvent B) to 10% solvent A and 90% solvent B over 9min, as a
mobile phase.
Cyclic RGD (ARG-GLY-ASP) peptide coupling was performed as
described previously (Schiffelers et al, 2003). In brief, 4nM cRGD
peptide (JPT, Berlin, Germany) per mM total lipid was added after
deacetylation of the peptide in 0.5 M hydroxylamine solution and
incubated for 1h at room temperature. Unloaded ZD6126 and
unbound RGD were separated from the liposomes by PD-10
column (Amersham, Piscataway, NJ, USA). To obtain 10mgml
 1
ZD6126 liposomal formulations, liposomes were concentrated by
ultracentrifugation for 1h at 60000 r.p.m. (Beckman, Fullerton,
CA, USA).
In vitro cell toxicity
Human umbilical vein endothelial cells (HUVECs), B16F10 murine
melanoma cells and J774A.1 murine tumour-derived macrophages
were grown at 371C and 5% CO2 conditions in EGM-2 (Cambrex,
East Rutherford, NJ, USA) and heat-inactivated FBS-supplemented
Dulbecco’s modified Eagle’s medium, respectively. Cells were
seeded (1 10
4 cells per well) in 96-well plates 24h before samples
were added. ZD6126 formulations (0.01–100mM) were incubated
with the cells for 24h and finally an XTT cell viability assay was
performed (Scudiero et al, 1988).
Pharmacokinetics studies
PEG-liposomal (RGD-coupled) and free ZD6126 (20mgkg
 1)
was administered i.v. in the tail vein to C57Bl/6 mice (n¼3 per
group). Blood samples were collected by cardiac puncture
at various time intervals (5min to 48h) after dosing.
Plasma levels of ZD6126 and ZD6126 phenol were determined by
tandem mass spectrometry (PE Sciex API 3000 spectrophoto-
meter). The limits of quantification were 10ngml
 1 for ZD6126
and ZD6126 phenol.
Immunohistochemical analysis
ZD6126-loaded RGD-PEG-liposome (20mgkg
 1)-treated B16F10
mice were killed at several time points and tumours (4100mm
3),
livers and spleens were excised, snap-frozen in liquid nitrogen and
stored at  801C. After acetone fixation, 5mms e c t i o n sw e r es t a i n e d
for the RGD peptide. Staining of RGD was performed as described
previously (Schraa et al, 2002). In brief, sections were incubated
with polyclonal anti-RGD antibodies raised in rabbits (diluted
1:1000 in PBS/FCS 5% buffer), followed by immunoperoxidase
staining. Subsequently, a second goat anti-rabbit horseradish
peroxidase-labelled antibody (diluted 1:100, Dako A/S, Carpinteria,
CA, USA) and a third rabbit anti-goat horseradish peroxidase-
labelled antibody (1:100, Dako A/S) were added. For the F4/80
(pan macrophage marker) staining (Lee et al, 1985), monoclonal
rat a-anti mouse (clone CI:A3-1, Serotec, Raleigh, NC, USA) 1:40
(in PBSþBSA 1%) was used as primary antibody after serum
blocking with normal rabbit serum (1:20 in TBS-Tween 20).
Subsequently, staining of endogenous peroxidase and biotin
blocking (Vector, Orton, UK) was performed followed by incubation
with biotinylated rabbit anti-rat IgG (HþL, 1:400 in PBS, Vector)
and horseradish peroxidase-streptavidin (1:400 in PBS, Vector).
For both staining procedures, 3-amino-9-ethylcarbazole (Sigma-
Aldrich, St Louis, MO, USA) was used as a substrate and
hematoxylin (Sigma-Aldrich) for counterstaining. Slides were
mounted in Kaiser’s glycerol-gelatin medium (Merck, Darmstadt,
Germany) and visualised by light microscopy (Nikon TE2000-U).
RGD-staining quantification
Microscopic fields (200  magnified) per sample were analysed for
stained regions (sum of substrate-stained pixels) with compu-
terised image analysis programme (Image-Pro
s plus 4.5 for
windows). Computer software was used to quantify total substrate
(red) stained areas. Finally, data were corrected for tissue weight to
calculate total staining per gram of tissue.
Tumour necrosis
Necrosis was assessed by light microscopy. B16.F10
tumour-bearing mice (n¼10 per group, average tumour
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Figure 2 Pharmacokinetics of ZD6126 (A) and ZD6126 phenol (B) after administration of free and liposomal ZD6126 in non-tumour-bearing C57Bl/6
mice. Formulations were injected in a single bolus intravenous dose of 20mgkg
 1. Groups (n¼3) consisted of free ZD6126 ( ), PEG-liposomal ZD6126
(m), and RGD-PEG-liposomal ZD6126 ( ). At selected time point, post-injection blood was collected and ZD6126 and ZD6126 plasma levels were
measured by tandem mass spectrometry. All points are averages of three mice±s.d. Additionally, AUC values t1/2, Cmax and Tmax values were calculated.
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ssize¼255±143mm
3)weretreatedwithfreeZD6126(100mgkg
 1),
RGD-liposomal ZD6126 (100mgkg
 1) or liposomal PBS control and
tumours were excised 24h afterwards. Subsequent to fixation in 10%
buffered formalin and standard processing to paraffin wax blocks,
sections (5mm) were prepared and stained with H&E. The level of
necrosis was scored blinded to treatment details by a pathologist.
Scores can vary between 1 and 10, where 1 specifies 0–10% necrosis
and 10 denotes 490–100% necrosis (Blakey et al, 2002b). For the
free ZD6126 200mgkg
 1 dose, multiple images were fitted together
using PhotoFit Harmony software.
In vivo therapeutic efficacy studies
C57Bl/6J mice were injected subcutaneously in the right flank with
1 10
6 B16F10 melanoma cells at day 0. At day 11 after tumour cell
inoculation, when tumours reached a size of X100mm
3, PBS
liposomes, free ZD6126 (100mgkg
 1), PEG-liposomal ZD6126
(100mgkg
 1) or RGD-PEG-liposomal ZD6126 (100mg/kg) was
administered i.v. in the tail vein. Tumour size was measured every
second day, using digital calipers. For the multiple 100mgkg
 1
dose study, mice were also treated for the first time at day 11
followed by two injections at 4-day intervals (days 15 and 19).
Tumour volumes were calculated using the following equation:
V¼(A 0.52) B
2, where A is the largest and B is the smallest
superficial diameter. Mice were killed when tumour reached a
volume of 2000mm
3, if tumour had broken open through the skin
or when animals appeared moribund.
Animal studies
All animal studies were validated and performed according to
Utrecht University ethical guidelines, in line with national
laboratory animal regulations.
Statistical methods
For the necrosis scores, Mann–Whitney rank-sum test was used,
and for analysis of the survival curves the Log-rank test was
applied.
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Figure 3 Histological examination of tumour, liver, and spleen. (A) Semi-quantification of RGD-stained tumour, spleen, and liver sections over time.
Values are calculated per gram tissue. Bars represent means±s.e. (B) Tumour rim staining of RGD 24h after injection of RGD-PEG liposomes containing
ZD6126 (20mgkg
 1). (C) RGD staining is seen only in the red pulp of the spleen (4h post-injection). (D) RGD immunostaining of an RGD-PEG-liposomal
ZD6126 (20mgkg
 1)-treated mouse liver, excised 1h after injection. (E) Untreated control liver stained for F4/80-positive macrophages (all scale bars
represent 100mm).
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Liposome-encapsulated ZD6126
ZD6126-loaded PEG liposomes or RGD-PEG-liposomes were
prepared by the lipid-film hydration method. The amount of
encapsulated drug increased proportionally with the total amount
of ZD6126 added. A positive correlation between liposome
diameter and amount of encapsulated drug was observed,
indicating that the ZD6126 is primarily present in the aqueous
interior of the liposomes. The liposomes that were used in these
studies had a mean diameter of 0.15mm and a polydispersity index
below 0.2, indicating limited variation in particle size. Hydration of
100mM total lipid with 40mgml
 1 ZD6126 yielded an average
concentration of 7.5±2.5mg ZD6126 per ml of liposome suspen-
sion. ZD6126-loaded liposomes showed less than 10% leakage in
PBS, at 37 and 41C over 3 weeks. Particle size was maintained over
this time period.
In vitro cytotoxicity
Cytotoxicity, as measured by XTT assay (Scudiero et al, 1988), of
free and liposome-encapsulated ZD6126 was examined in three cell
types: B16.F10 murine melanoma cells, HUVECs and murine
macrophages (J774A.1). After 24h incubation, ZD6126 at
drug concentrations below 1mM did not induce cytotoxicity
(Figure 1A–C). However, ZD6126 concentrations of 1mM and
above for free ZD6126 and 10mM and above for liposomal ZD6126
reduced viability for all cell types (Figure 1A–C). In contrast, for
both RGD-PEG-liposomes and PEG-liposomes, ZD6126 toxicity
was detected only at 10mM and above. These results suggest that
over 90% of the drug remains encapsulated in the liposomes for at
least 24h in cell culture medium. Viability of J774A.1 macrophages
was reduced by maximum 75% compared with vehicle-treated
controls. Human umbilical vein endothelial cells and B16.F10
melanoma cells showed only moderate reductions in cell viability
of about 50 and 30%, respectively.
Pharmacokinetics of ZD6126 and ZD6126-phenol after
intravenous administration of liposome-encapsulated
ZD6126
Intravenously administered free ZD6126 (20mgkg
 1) was
rapidly (t1/2¼0.04h) converted to ZD6126-phenol and quickly
(t1/2¼0.08h) cleared from the blood (Figure 2A and B). Both PEG-
liposome and RGD-PEG-liposome formulations of ZD6126 showed
identical pharmacokinetics. Calculated ZD6126 half-life for both
formulations was approximately 10h, which is typically observed
for PEG-liposome-encapsulated drugs in mice (Metselaar et al,
2003). ZD6126 concentrations were higher than 10mM, a level
causing in vitro cell toxicity, even at 48h after injection. ZD6126
phenol levels showed increasing plasma levels during the first 8h
after injection. Subsequently, a steady decrease was observed.
Tissue localisation of RGD-PEG liposomes
To investigate tumour, liver and spleen distribution profile of i.v.
injected RGD-PEG liposomes, we performed immunohistochem-
istry using a rabbit anti-RGD antibody to detect the RGD peptides.
Semi-quantification of RGD staining showed high spleen accumu-
lation and comparable tumour and liver accumulation per gram
tissue (Figure 3A). Tumour and liver tissue staining for RGD was
comparable, although in the tumour RGD, staining was more
pronounced in the rim (Figure 3B). In the spleen, a staining
pattern largely confined to the red pulp was observed consistent
with an association with macrophages (Figure 3C). In liver tissue,
RGD staining produced a punctuated macrophage-like staining
pattern very similar to that obtained following staining for F4/80
antigen, a marker expressed on a wide range of mature tissue
macrophages (Lee et al, 1985) (Figure 3D and E).
Evaluation of tumour necrosis
B16.F10 melanoma-bearing mice were treated i.v. with 100mgkg
 1
free ZD6126, RGD-liposomal ZD6126, or vehicle. Tumours were
excised at 24h after injection. Tumour sections were visually
scored for necrosis by a pathologist (FRW) blinded to treatment.
Vehicle-treated controls showed some necrosis. In this tumour
model, free ZD6126 (100mgkg
 1) did not show a significant
difference in the degree of tumour necrosis compared with vehicle-
treated controls (Figure 4A). In contrast, RGD-liposomal ZD6126
(100mgkg
 1 ZD6126)-treated tumours showed a significantly
increased tumour necrosis score compared with control. As a
control, 200mgkg
 1 free ZD6126 was administered and showed
490% necrosis 24h after injection (Figure 4B).
Therapeutic efficacy of a single-dose treatment schedule
B16F10 melanoma-bearing mice were treated with 100mgkg
 1 free
ZD6126 or encapsulated in PEG liposomes or RGD-PEG liposomes.
Tumour growth was compared with vehicle-treated controls.
Growth curves of individual mice showed very rapid growth
kinetics for the PEG-liposomal PBS-treated control mice, which are
typically observed in this melanoma model (Figure 5A). For mice
treated with free ZD6126, an initial growth arrest was seen, which
lasted less than 4 days after treatment (Figure 5B). After this initial
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Figure 4 (A) Necrotic score of tumour tissue 24h after administration
of vehicle, free ZD6126 100mgkg
 1, and RGD-PEG-liposomal ZD6126
100mgkg
 1. &, mean of data; —, median; , highest and lowest value;
, interquartile range (25–75%). P-values: Mann–Whitney rank-sum test.
(B) Tumour section (H&E-stained) of a mouse treated with 200mgkg
 1
free ZD6126, 24h after intravenous injection. N¼necrotic area and VR¼
viable rim; scale bar represents 1mm.
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sdelay, tumour growth resumed. Both PEG-liposomal (Figure 5C)
and RGD-PEG liposomal (Figure 5D) encapsulated ZD6126
arrested tumour growth for much longer periods of time.
Statistical comparison of groups was performed using survival
analysis. Death of animals was recorded when tumour size
exceeded 2000mm
3 or when mice appeared moribund. Each of
the ZD6126-treated groups showed significant survival advantages
over vehicle-treated controls. Between ZD6126 treatments, free
drug was less effective than either liposome formulations.
Comparing the two liposome formulations, no statistically
significant difference was noted.
Therapeutic efficacy in a multiple-dose treatment schedule
B16F10 melanoma-bearing mice were treated three times (every 4
days) i.v. with 100mgkg
 1 free ZD6126 or the same dose
encapsulated in PEG liposomes or RGD-PEG liposomes. Tumour
growth was compared with vehicle-treated controls (Figure 6A).
Similar to the single-treatment regime, growth delay was observed
for all three ZD6126 formulations. Free ZD6126 showed a
prolonged antitumour effect compared with the single-dose study
(Figure 6B). However, tumour size still increased and the majority
of animals were killed before the third planned injection on the day
after tumour cell inoculation. Also for PEG- and RGD-PEG
liposome formulations, a more pronounced tumour growth delay
was shown in comparison with the single-dose experiment (Figure
6C and D). However, following the third injection, most animals in
the PEG-liposomal ZD6126 and RDG-PEG-liposomal ZD6126
groups became moribund or showed clinical signs within 24h of
injection and were killed.
DISCUSSION
Vascular disrupting agents have been widely explored as
antitumour agents in preclinical and clinical studies. In this study,
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Figure 5 Individual tumour growth curves and survival curve after a single dose of 100mgkg
 1 ZD6126 formulations administered when tumours
reached X100mm
3 (11 days after tumour cell inoculation). (A) Control vehicle (n¼10). (B) Free ZD6126 100mgkg
 1 (n¼9). (C) PEG-liposomal
ZD6126 100mgkg
 1 (n¼8). (D) RGD-PEG-liposomal ZD6126 100mgkg
 1 (n¼8). (E) Survival curve of all four groups (mice out of experiment when
tumours reached 42000mm
3, when tumours broke open through the skin and when mice were moribund). P-values: vehicle vs free ZD6126, P¼0.0070,
vehicle vs PEG-liposomal ZD6126, Pp0.0001, vehicle vs RGD-PEG-liposomal ZD6126, P¼0.0004; free ZD6126 vs PEG-liposomal ZD6126, P¼0.0004;
free ZD6126 vs RGD-PEG-liposomal ZD6126, P¼0.0315; and PEG-liposomal ZD6126 vs RGD-PEG-liposomal ZD6126, P¼0.0944.
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swe have shown substantial improvement in the antitumour activity
of the VDA ZD6126 by liposomal encapsulation. Water-soluble
ZD6126 was stably associated with the liposomes. In vitro
cytotoxicity studies confirmed limited leakage from the liposomes.
Human umbilical vein endothelial cells, murine melanoma cells
(B16.F10), as well as macrophages (J774A.1) all showed a 10-fold
decreased cytotoxicity for the liposome-encapsulated ZD6126 as
compared with the free drug, which is consistent with o10% drug
release in buffer. This conclusion is supported by previous studies
that showed limited cellular interaction of PEG liposomes
(Du et al, 1997; Miller et al, 1998) The experiment also showed
that ZD6126 cytotoxicity may occur after continuous exposure over
24h to relatively high drug concentrations, which is in agreement
with previous findings (Blakey et al, 2002a). For the free drug, such
prolonged exposure is unlikely to occur in vivo in mice, as both the
parent drug ZD6126 and its active moiety ZD6126 phenol have a
short half-life. However, as PEG liposomes tend to accumulate in
macrophages, sustained high levels of ZD6126 may be reached in this
cell type after liposomal administration of ZD6126.
Intravenously administered free ZD6126 and its dephosphory-
lated active form ZD6126 phenol were cleared from the circulation
within 15min (Figure 2). These observations are in accordance
with previously described distribution profiles and pharmaco-
kinetic data for rat and human pharmacokinetics (Blakey et al,
2002a; Radema et al, 2002; Scurr et al, 2004; Beerepoot et al, 2006).
In contrast, pharmacokinetics of both PEG-liposomal and
RGD-PEG-liposomal encapsulated ZD6126 showed a much longer
half-life irrespective of the presence of the targeting peptide, which
is probably due to macrophage saturation upon high lipid dose
administration. A comparison of AUC between free and liposomal
ZD6126 translates into a 160-fold increase over a 48h period.
ZD6126 phenol levels after a single dose of liposomal ZD6126 were
detectable for at least 2 days. This translates into 40-fold increased
AUC values over 48h period after injection. Levels of ZD6126
phenol in plasma peaked at 8h after injection. This is probably the
result of intracellular processing of the ZD6126-containing
liposomes by the MPS. At this time point, the MPS organs are
responsible for the majority of liposome clearance from the
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Figure 6 Individual tumour growth curves and survival curve after multiple (3  every 96h, days 11, 15, and 19 after tumour cell inoculation) dose of
100mgkg
 1 ZD6126 formulations administered when tumours reached X100mm
3.( A) Control PBS liposomes (n¼7). (B) Free ZD6126 100mgkg
 1
(n¼9). (C) PEG-liposomal ZD6126 100mgkg
 1 (n¼9). (D) RGD-PEG-liposomal ZD6126 100mgkg
 1 (n¼8). (E) Survival curve of all four groups (mice
out of experiment when tumours reached 42000mm
3, when tumours broke open through the skin or when mice were moribund). P-values: vehicle vs free
ZD6126, P¼0.0097; vehicle vs PEG-liposomal ZD6126, Pp0.0001, vehicle vs RGD-PEG liposomal ZD6126, Pp0.0001; free ZD6126 vs PEG-liposomal
ZD6126, P¼0.0014; free ZD6126 vs RGD-PEG liposomal ZD6126, P¼0.0006, and PEG-liposomal ZD6126 vs RGD-PEG-liposomal ZD6126, P¼0.5737.
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scirculation (Schiffelers et al, 2003). Subsequent release of the
converted prodrug from the MPS cells into the circulation could
explain the observed profile. Quantifying immunohistochemical
staining of RGD-PEG liposomes in tumour, liver and spleen tissue
revealed high splenic uptake and comparable levels of liver and
tumour staining. These findings are consistent with the tissue
distribution profiles of RGD-PEG liposomes (Schiffelers et al,
2003). The RGD-PEG-liposome staining in the tumour showed
some evidence of tumour rim accumulation. The B16.F10
melanoma model used in these studies was not very sensitive to
free ZD6126 treatment at the 100mgkg
 1 dosing schedule.
However, 200mgkg
 1 free ZD6126 showed 490% necrosis 24h
after injection (Figure 4B), indicating that this model is
intrinsically sensitive. The free drug did not significantly increase
the degree of tumour necrosis compared with controls, and the
tumour growth delay induced by single or multiple doses of free
ZD6126 was modest. In contrast, RGD-PEG-liposomal ZD6126
significantly increased tumour necrosis. This may be the result of
an improved tumour localisation of ZD6126 as compared with the
free drug leading to increased drug exposure of the endothelial
cells in the tumour.
For both RGD-PEG and PEG liposomes, tumour growth delay
persisted much longer than with free ZD6126, most likely as a
result of increased local and systemic drug exposure. This is in
contrast to a single earlier report, using actively targeted RGD-PEG
liposomes to deliver the VDA combretastatin A4 (Pattillo et al,
2005) where there was no evidence of prolonged tumour growth
delay. The unstable association of combretastatin A4 with the
liposomal bilayer may be responsible for the absence of substantial
antitumour effects. The choice of a water-soluble prodrug such as
ZD6126, which is stably entrapped into the aqueous interior, may
be critical for successful target tissue delivery.
There was no apparent difference between the two liposome
formulations, indicating that the association of RGD-PEG lipo-
somes with tumour endothelium does not improve therapeutic
efficacy compared with PEG liposomes, which do not display a
specific endothelial cell interaction. To intensify the antitumour
effects, a multiple dosing schedule was evaluated. Multiple doses of
free drug prolonged the antitumour effects. Also for the liposomal
formulations, multiple injections significantly prolonged tumour
growth delay; however, after the third injection, some mice became
moribund. It is at present unclear why the liposomal ZD6126 was
not tolerated after the third injection, as toxicological studies have
not been performed, although decreased tolerability could result
from an altered tissue distribution profile and/or increased drug
exposure. The time interval between doses of liposomal ZD6126 to
optimise antitumour effects and minimise toxicity warrants further
investigation.
In conclusion, liposomal encapsulation of ZD6126 improves
monotherapeutic antitumour activity compared with a similar
dose of free ZD6126. The prolonged antitumour effects observed
for the liposomal formulations could also be beneficial for
combination therapy strategies, extending the time to attack
remaining viable tumour cells. RGD-PEG liposomes, targeted to
angiogenic endothelial cells, proved to be no more efficacious than
passively targeted PEG liposomes, indicating that active targeting
and cell-specific delivery of VDAs do not offer an advantage over
target tissue delivery in this tumour model. After phosphatase
cleavage, ZD6126 phenol can traverse cellular membranes and
bind to its intracellular target, tubulin, which could reduce the
importance of target cell-specific delivery. This would mean that
locally accumulated liposomes serve as a depot for ZD6126,
increasing tumour site drug exposure compared with the rapidly
cleared free ZD6126. This increase in tumour drug exposure could
also induce alternative mechanisms of action for ZD6126,
including tumour cell and tumour-associated macrophage toxicity,
which could contribute to overall antitumour effects.
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